background: The influence of LH on serum progesterone rise during gonadotrophin stimulation is a matter of debate. The purpose of this analysis was to assess the impact of supplementation with 'LH activity' products on serum progesterone changes before hCG administration in GnRH analog-treated women.
Introduction
The issue of serum progesterone rise on the day of hCG administration (serum progesterone hCG ) during controlled ovarian stimulation (COS) is still a matter of several controversies. As recently emphasized, serum progesterone rise observed during the final stages of COS is not actually premature luteinization because it takes place in patients treated with GnRH analogs, which fully control further LH surge. Luteinization, the process by which the mature follicle is transformed into a corpus luteum, is mainly induced by an LH surge (Murphy, 2000) . In contrast, the subtle and gradual increase in progesterone levels observed during the last day of ovarian stimulation reflects only the total amount of progesterone secreted by maturing follicles in the absence of any premature uncontrolled LH surge.
Many questions have been raised regarding the incidence of progesterone elevation in GnRH-analog-controlled cycles specifically on the impact on cycle IVF outcome. A meta-analysis (Venetis et al., 2007) concluded that there was a lack of evidence for a negative impact of high P-values on implantation rate. However, this conclusion has recently been challenged (de Ziegler et al., 2008; Fleming, 2008; Kolibianakis et al., 2011; Kyrou et al., 2011) for several reasons: results confounded by the use of different GnRH analog protocols, methodological flaws such as the unreliability of commercial non-extraction assays (Coucke et al., 2007) , arbitrary choice of defined threshold (0.9 ng/ml) while the use of receiver operator characteristics curve might have been more appropriate. Using this approach, Bosch et al. (2010) reported a negative impact of serum progesterone increase with a threshold value of 1.5 ng/ml in a large single-center study where GnRH agonist and antagonist cycles were analyzed separately. This threshold value has been proposed in a recent study that additionally emphasizes the predictive value of progesterone/estradiol (E 2 ) ratio (Elgindy, 2011) . Furthermore, the consequences of serum progesterone rise on IVF outcome might be drastically different depending on whether it occurs in women with a strong or weak response to COS. Indeed, a low clinical pregnancy rate was mainly observed when the response to COS was weak (Fanchin et al., 1997) . Therefore, confounding factors such as patients' ovarian reserve, oocyte and embryo quality need to be also considered when assessing the consequences of serum progesterone rise on cycle outcome following COS (De Ziegler et al., 2008; Younis, 2011) .
The potential negative impact of elevated progesterone on cycle outcome seems to be related to inadequacy of the endometrium as demonstrated in oocyte donor program (Melo et al., 2006) and in studies where endometrial gene expression has been assessed Van Vaerenberg et al., 2011) . However, it has been suggested that the endometrial receptivity is only temporally defective because blastocysts transferred on Day 5 would have an excellent potential for implantation even in the presence of high progesterone levels at the time of hCG (Papanikolaou et al., 2009; Elgindy, 2011) . Whether endometrial receptivity is able to recover from a detrimental impact observed when embryos are replaced on Day 3 remains to be elucidated. Nevertheless, these data emphasize the relevance of measuring serum progesterone values at the time of hCG in order to adjust the strategy for embryo transfer.
Many factors have been associated with an increased risk of progesterone rise during GnRH analog-controlled cycles. Several studies have emphasized the critical role of ovarian parameters such as the total dose of FSH administered as well as the intensity of the ovarian response assessed by serum E 2 levels on the day of hCG and the number of follicles or oocytes on the day of ovarian pick-up (Filicori et al., 2002a,b; Bosch et al., 2003 Bosch et al., , 2005 Bosch et al., , 2008 Andersen et al., 2006; Kyrou et al., 2009a,b) . These data suggest that the increase in granulosa cells activity is the main driver of progesterone elevation. They also show that a multivariate analysis is absolutely required to separate confounding factors.
In this context, the role of LH is still unclear due to the complexity of the regulation of ovarian steroïdogenesis by gonadotrophins. If we have a closer look at the role of LH (Payne and Hales, 2004) , it is critical to separate the effects on theca and granulosa cells ( Fig. 1) . † On the one hand, LH constitutively acts on theca cell receptors to stimulate Cytochrome P450 CYP 17 enzymatic complex (17 hydroxylase and 17-20 lyase activities), responsible for the conversion of progesterone (D4 pathway) or pregnenolone (D5 pathway) to 17-hydroxylated products and androgens. The actual resulting effect is a decrease in progesterone production by theca cells. In contrast, LH acts on 3b hydroxysteroid dehydrogenase (HSD) type II to stimulate the conversion of pregnenolone to progesterone. Therefore, the overall effect of LH on theca cell progesterone production depends on the balance between these enzymatic activities. † On the other hand, LH acts on granulosa cells when LH receptors have been induced by FSH at the later stage of follicular phase.
In vitro experiments have clearly demonstrated that LH has a synergistic effect with FSH on granulosa cells to stimulate progesterone production (Young et al., 1992; Lindeberg et al., 2007) , and that LH is far more potent than FSH on granulosa cells to produce steroids as assessed by cAMP accumulation (Young et al., 1994) .
This complex biphasic and development-related effect of LH on progesterone production is likely to explain the controversy regarding the actual role of LH in serum progesterone elevation before hCG administration.
Few studies have been published so far on the role of endogenous LH environment. Most of them concluded for the lack of correlation between serum progesterone elevation and LH levels or the area under the curve of serum LH during the time of stimulation (Ubaldi et al., 1996; Bosch et al., 2003 Bosch et al., , 2005 . However, a close relationship between serum LH and progesterone in GnRH agonist cycles has been recently observed in two other reports (Hugues et al., 2011; Yding Andersen et al., 2011) . These divergent conclusions may be explained by the use of different assays that cannot reflect LH bioactivity. It has been also recently reported that serum progesterone concentrations at the time of hCG administration (serum progesterone hCG ) are lower following GnRH antagonist regimens when compared with GnRH agonist protocols (Bosch et al., 2010) . However, it is still uncertain whether this observation can be explained by the different endogenous LH environment created by each protocol or by other confounding factors such as ovarian parameters.
The purpose of this review was to evaluate the impact of exogenous 'LH activity' products on progesterone elevation before triggering of ovulation. Over the last three decades, several molecules have been Figure 1 Effects of LH on progesterone production during the follicular phase. Left part: LH acting on theca cells via constitutive receptors present during the whole follicular phase has a dual effect on progesterone synthesis. Stimulation of 3b HSD type II induces a positive effect on progesterone production. Activation of CYP 17 which converts progesterone and pregnenolone to 17 OH derivates reduces progesterone synthesis. The overall effect depends on the respective activation of these two enzymatic activities Right part: LH acts on granulosa cells via receptors present only during the late follicular phase. LH activates 3b HSD type II enzymatic activity with a positive effect on progesterone production. 3b HSD II: 3 beta hydroxysteroid deshydrogenase type II CYP 17: Cytochrome P450 17 a-hydroxylase. (260) .17/6.9 (0.5)* 11.8 (0.9)* 2.245 (180)* 14.7 (0.6)* NS
Continued
The effect of 'LH activity' supplementation on serum progesterone manufactured to provide 'LH activity'. hMG, a urinary-derived product with both FSH and LH activities, were initially used for clinical practice. The 'LH activity' was supplied by a combination of LH and hCG to provide the equivalence of 75 IU standard of LH biological activity and to comply with the regulation of the European and US Pharmacopea. Following subsequent purification (hMG-HP), the nature of LH activity was switched to hCG alone at a concentration of 10 IU, equivalent to 75 IU LH in term of biological activity. Recombinant LH, launched in the early 2000s, gave the opportunity to use FSH and LH separately with different ratios. Finally, urinary hCG and, more recently, recombinant hCG have been also used to provide 'LH activity' in addition to FSH. Therefore, clinical trials published in peer reviews and dealing with a comparative analysis of the effects of FSH alone or associated with 'LH activity' products on serum progesterone hCG in cycles where endogenous LH surge was controlled by GnRH analog protocols were analyzed. For reasons previously mentioned, the influence of confounding factors related to the ovarian response to FSH was also considered. In contrast to meta-analysis, this systematic review was not aimed at providing statistical analysis. The main objective was to identify studies where serum progesterone hCG determination was available and to assess the specific effect of the 'LH activity' supply on serum progesterone variation. since unpublished studies cannot be adequately assessed for their design and quality. All publications released from 1980 to 2010 were reviewed.
Materials and Methods

Identification of studies
Studies identified
Literature search yielded 108 studies that were potentially able to answer the research question. Fifty-six studies were set up to compare the effects of hMG/hMG-HP versus urinary/recombinant FSH. Twenty one of them provided data regarding serum progesterone hCG and/or follicular fluid progesterone concentrations on the day of oocyte retrieval. Among the 34 studies reporting comparative data between patients treated with urinary/recombinant FSH alone or with addition of recombinant LH, six reported the values of serum progesterone hCG . Finally, 18 studies were performed to compare the effects of FSH alone or with addition/substitution with hCG. In seven of them, serum progesterone hCG were available.
Data extraction
The following data were recorded from each study where serum progesterone hCG value was available: authorship, review and year of publication; type of studies (retrospective or prospective/randomized); interventions; characteristics of population; GnRH analog protocols; gonadotrophin protocols including FSH stimulation regimen and the protocol for 'LH activity' supply; number of enrolled patients in each group; ovarian parameters including serum estradiol (E 2 ) and serum progesterone hCG , the number of large and medium sized follicles and/or oocytes, duration of ovarian stimulation and total FSH dose used.
Results
The results are presented according to the type of 'LH activity' added to FSH.
Studies comparing hMG or hMG-HP versus urinary or recombinant FSH
Of the 56 studies comparing hMG and FSH, 21 provided information regarding P values. Progesterone concentrations were measured in serum at the time of hCG administration in 17 studies, in follicular fluid at the time of oocyte retrieval in two studies and in both serum and follicular samples in 2 studies. Details of the studies are shown in Tables I and II . The intervention was IVF or ICSI in a majority of studies (16/21), oocyte donation in one study and IUI) in four studies.
The most prescribed GnRH analog regimen was the GnRH agonist protocol (17 long and 1 short) while, in only two studies, a GnRH antagonist protocol was used. In one study, both GnRH analogs were compared. The effect of 'LH activity' supplementation on serum progesterone
Regarding the choice of gonadotrophins, urinary FSH preparations were compared with hMG in 10 studies. In another six studies, comparisons were performed between hMG and recombinant FSH. Finally, hMG-HP preparations were compared with recombinant FSH (follitropin alpha) in six studies.
The analysis of follicular fluid progesterone concentrations following hMG or hMG-HP administration showed the absence of significant difference in three studies, while a significant lower value than in rFSH-treated cycles was reported in one study. In that study, the number of developing follicles and retrieved oocytes was significantly lower in patients treated with hMG-HP.
In 16 of 19 studies reporting data on serum progesterone hCG values, no significant difference was observed. In the three others, serum progesterone hCG concentrations were significantly lower in patients treated with hMG when compared with those treated with FSH. In these studies, different GnRH analog protocols were used and the ovarian response following hMG administration was significantly lower than after FSH treatment. In addition, no correlation was observed between the duration of ovarian stimulation and the value of serum progesterone hCG administration.
Therefore, this analysis-comparing the effects of hMG and FSH preparations on serum progesterone rise eventually-shows that the occurrence of a serum decrease after hMG treatment is restricted to a small proportion of patients (15.8%) and is constantly associated with a weaker ovarian response assessed by the number of follicles and oocytes.
Studies comparing FSH alone versus FSH and recombinant LH
Study details are set out in Tables III and IV. In 6 of 34 studies, serum progesterone hCG values were reported. The intervention was IVF-ICSI in these six studies. The GnRH analog used was an agonist (2), an antagonist (3) or both (1). Recombinant FSH was constantly used and comparison was performed with cycles supplemented by recombinant LH (rLH) doses (range: 75-225 IU) prescribed from the beginning (2) or the middle part of the stimulation (4).
In five studies, no significant difference in serum progesterone hCG was observed. In one study, serum progesterone hCG was significantly lower in patients supplemented with rLH when compared with FSH alone. In that study, the administration of LH (75 -150 IU) was started on Day 1 of the stimulation, and the number of follicles was significantly reduced, at least in older women (36-39 years) whose duration of ovarian stimulation was significantly longer.
Therefore, this analysis-comparing the effects of FSH alone or in addition with rhLH-cannot demonstrate any consistent effect of rLH on serum progesterone rise. The decrease in serum progesterone observed in the study where rhLH administration was started on Day 1, was associated with a diminished ovarian response to COS. 
Studies comparing FSH alone versus FSH and hCG
Among 18 studies published from 1999 to 2010 (Tables V and VI) , seven presented data on serum progesterone hCG levels. The intervention was IVF-ICSI (5) or IUI (2). In four studies, a GnRH agonist protocol was prescribed, whereas a GnRH antagonist was used in two and both GnRH analogs were used in one study. Recombinant FSH was prescribed in six of seven studies, and hCG administration was started from S1 or S2 in two studies and from the mid follicular phase in the five others.
In five studies, no significant difference in serum progesterone concentrations could be observed between patients treated with FSH and hCG when compared with those treated with FSH alone. In contrast, in two studies, a significant increase in progesterone AUC or progesterone hCG value was observed. In both studies, hCG administration was started when FSH was discontinued (Day 8 of ovarian stimulation or at a follicular size .12 -13 mm) and the total dose of FSH was significantly lower in patients treated with hCG when compared with those treated with FSH alone. In addition, in one of these two studies, the duration of stimulation was significantly shorter in patients supplemented with hCG.
Therefore, this analysis comparing serum progesterone rise at the time of triggering of ovulation in women treated with FSH alone or a combination of FSH-hCG shows that hCG administration can be associated with a rise in serum progesterone. 
Discussion
This review does not demonstrate any significant impact of 'LH activity' administration on serum progesterone elevation at the time of hCG administration. Indeed, this analysis of 108 studies comparing administration of FSH alone or in combination with products with LH activity (hMG, rhLH and hCG) shows that: (i) assessment of serum progesterone hCG values was recorded in 34 of 108 published reports (31.5%). (ii) A significant decrease in serum progesterone hCG was observed following administration of 'LH activity' products in four of them (11.8%), while a significant increase in serum progesterone was reported in two others (5.9% the first report on this issue (Schoolcraft et al., 1991) , both the incidence and the effect on cycle outcome are still a matter of debate.
As recently emphasized (Fleming, 2008) , one of the most clinically relevant drawbacks is related to serum progesterone measurement usually done by the commercial kit assays with a huge variability (Coucke et al., 2007) . In most of the studies reviewed, this methodological drawback was minimized by the use of the same assay for comparison between treatment groups. In contrast, the determination of the threshold P-value over which cycle outcome could be altered is clearly dependent on the choice of serum progesterone assay. This heterogeneity between progesterone assays can probably account for the divergent conclusion between studies. The main objective of this review was to assess the specific impact of 'LH activity' products on the risk of serum progesterone hCG . However, as reported in several studies, many confounding factors are involved in the process of serum progesterone rise. The most significant is actually the intensity of the ovarian response to FSH. Indeed, a clear relationship exists between serum progesterone hCG values and the total FSH dose, E 2 values at the time of hCG as well as the number of recruited follicles or retrieved oocytes (Filicori et al., 2002a,b; Bosch et al., 2003 Bosch et al., , 2005 Bosch et al., , 2008 Andersen et al., 2006; Kyrou et al., 2009a,b) . This relationship has been commonly explained by the large recruitment of follicles, each producing progesterone in granulosa cells under the influence of FSH stimulation, which activates 3b HSD type II enzymatic activity. This means that assessment of the role of 'LH activity' products on serum progesterone rise should take into account the intensity of the ovarian response.
It has also been recently suggested that the duration of the follicular phase could be an important determining factor in the occurrence of serum progesterone rise and, therefore, in the risk of cycle failure (Kyrou et al., 2011) . Indeed, increasing the duration of stimulation could result in a larger number of follicles and higher E 2 levels, which could negatively impact cycle outcome throughout an earlier expression of progesterone receptors (Kolibianakis et al., 2002; Kyrou et al., 2009a,b) . In accordance with this concept, it has been suggested that adjustment of the timing of hCG administration according to serum progesterone concentrations might improve cycle outcome (Harada et al., 1996) . However, in this review, no significant correlation could be observed between the duration of ovarian stimulation with LH-like activity products and serum progesterone rise.
The most clinically relevant finding of this analysis is that serum progesterone hCG values are poorly dependent on LH activity supplementation during COS. This lack of correlation can be explained by discrepancies in the design of studies.
Firstly, both materials and doses of 'LH activity' largely differed. Because biological activity of hCG is about 7-fold higher than LH, comparison between studies requires an adjusted analysis. In studies where LH supplementation was provided by rLH or hMG, the daily dose used (75 -150 IU rLH or 10 -20 IU hCG) was very close to the minimal effective dose (The European Recombinant Human LH Study Group, 1998) . In contrast, in patients supplemented with hCG, the usual range of daily dose was 50 -200 IU, equivalent to 350 -1400 IU of LH. This huge difference in 'LH activity' supply could partly explain the divergent effects on serum P-values. These data emphasize the need to better assess the effects of lower doses of hCG.
Most importantly, the relationship between the period of LH exposure and the effects on progesterone secretion is another critical issue to be addressed. Indeed, our analysis shows that a decrease in serum progesterone was mainly observed when 'LH activity' supply was administered from the beginning of COS. In contrast, patients who displayed an increase in serum progesterone received LH activity supplementation only during the late part of COS. This differential effect of 'LH activity' support is in agreement with the concept derived from physiology that the effects of LH upon progesterone secretion are development regulated: a dual effect of LH on theca cells is observed from the early follicular phase, while LH has a strong positive effect on progesterone output by granulosa cells during the late follicular phase. Therefore, it might be assumed that adding 'LH activity' from the beginning of the ovarian stimulation can result in a decreased progesterone production, while a stimulatory effect is predominantly observed when LH supplementation is provided during the late stage of COS. These data are in good accordance with a recent report showing that supplementation with rhLH from Day 1 of FSH stimulation has a positive impact on pregnancy rate in older patients , while it is not the case when addition of LH activity is provided on Day 6 -8 of the ovarian stimulation. Further clinical trials are required to confirm this hypothesis.
In conclusion, this review assessed the effects of supplementation with different 'LH activity' products on the elevation of serum progesterone during COS. Our data indicate that providing LH supplementation does not seem to have a consistent effect on progesterone output and that the major determining factor remains the degree of the ovarian response to FSH. This analysis also suggests that the timing of LH administration could have a significant impact on the occurrence of serum progesterone rise during COS. Further studies are required to better identify the optimal dose and timing for 'LH activity' supply.
